Assembly Biosciences (ASMB) Non-Current Debt (2010 - 2011)
Assembly Biosciences' (ASMB) quarterly Non-Current Debt came in at $1.3 million in Q2 2011, up 3.86% quarter-over-quarter from $1.3 million in Q4 2010.
Assembly Biosciences (ASMB) Non-Current Debt (2010 - 2011) Analysis & Trends
Assembly Biosciences' Non-Current Debt history runs 2 years deep, the most recent figure standing at $1.3 million for Q2 2011.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $1.3 million in Q2 2011; TTM through Jun 2011 was $1.3 million, a N/A change from a year earlier, with the FY2010 full-year figure at $1.3 million, changed N/A from the prior year.
- Non-Current Debt improved to $1.3 million in Q2 2011 per ASMB's latest filing, from $1.3 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.3 million in Q2 2011 and bottomed at $1.3 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Assembly Biosciences | 431.63 Mn | 205.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2011 | 1.32 Mn |
| Dec 31, 2010 | 1.27 Mn |